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Abstract: Attention-deficit hyperactivity disorder (ADHD) is one of the most common 
psychiatric disorders in young adults and causes significant psychosocial impairment 
and economic burden to society. Because of the paucity of long-term evidence and lack of 
national guidelines for diagnosis and management of adult ADHD, most of the data are based on 
experience derived from management of childhood ADHD. This article reviews the current evi-
dence for the diagnosis and management of adult ADHD with special emphasis on the role of 
methylphenidate hydrochloride preparations in its treatment. Methylphenidate hydrochloride, 
a stimulant that acts through the dopaminergic and adrenergic pathways, has shown more than 
75% efficacy in controlling the symptoms of adult ADHD. Although concern for diversion 
of the drug exists, recent data have shown benefits in preventing substance use disorders in 
patients with adult ADHD.
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Introduction
Attention-deficit hyperactivity disorder (ADHD), characterized by inattention, 
hyperactivity and/or impulsivity, causes significant impairment in psychological, 
occupational and social functioning in adults.1–3 It is estimated that 1% to 36% of 
children diagnosed with ADHD will continue to manifest symptoms into adulthood 
depending on the diagnostic criteria used.4 Estimates increase to between 40% and 60% 
when considering persistence rates in adults experiencing partial remission.4 Recent 
data suggest an adult ADHD prevalence rate of 4.4% with increased incidence in 
males.5 A retrospective analysis of National Ambulatory Medical Care survey over 
an 8-year period from 1996 to 2003 estimated a total of 10.5 million ambulatory 
adult ADHD visits accounting for 3.5% of 301 million adult mental health disorder 
visits.6 Adult ADHD diagnosis and management pose unique challenges to physicians 
because of an increased incidence of comorbid psychiatric and substance use disorders 
in this population. These comorbidities may result in substantial undertreatment in 
patients with adult ADHD because of providers attributing symptoms to the comorbid 
psychiatric disorder rather than adult ADHD.7 As a result, patients’ ADHD may remain 
untreated, which has been shown to result in impairment in patients’ self-care, mobility, 
cognition, and role functioning.3,5 Stimulants including methylphenidate, amphetamine 
and dextroamphetamine salts were the mainstay of treatment until atomoxetine, 
a nonstimulant, selective noradrenaline reuptake inhibitor, was approved for adult 
ADHD treatment. In this paper, we will briefly review the diagnosis and management Neuropsychiatric Disease and Treatment 2009:5 422
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of adult ADHD and detail the role of methylphenidate 
hydrochloride in the treatment of ADHD and comorbid 
disorders in adults.
Diagnosis
The diagnosis of adult ADHD poses challenges to 
clinicians as symptoms in adulthood may differ from those 
in childhood.8–10 For example, the DSM criteria require 
behaviors such as running or climbing excessively, which 
are unlikely to be symptoms present in adults.1 Further, 
many ADHD adults learn over time to compensate for their 
symptoms and thus may not manifest symptoms seen in 
childhood.9,10 Diagnosis can be further complicated when 
adults present without a childhood diagnosis of ADHD and 
have comorbid psychiatric and substance use disorders.3,8 
In a study by Faroane et al, most patients with adult ADHD 
were self-reported and self-referred, and there was significant 
delay in time to first diagnosis and initiation of treatment, 
especially in the primary care setting.3
Diagnostic criteria
The Diagnostic and Statistical Manual for Mental disorders, 
Fourth Edition Text Revision (DSM-IV-TR) requires 6 out 
of 9 symptoms of inattention (ie, failure to attend to detail, 
difficulty sustaining attention, not listening when spoken to, 
failure to follow through on tasks, organizational deficits, 
difficulty concentrating, losing items, distractibility, forget-
fulness) or hyperactivity/impulsivity (ie, fidgeting, difficulty 
staying seated, excessive running/climbing, difficulty playing 
quietly, acts as though “driven by a motor”, excessive talk-
ing, difficulty awaiting one’s turn, interrupting frequently, 
prematurely responding to questions) be present for a diag-
nosis of ADHD.1 In addition, the symptoms must be present 
before age 7 and result in significant impairment observable 
in at least two settings. The three ADHD subtypes according 
to DSM criteria are: predominantly hyperactive-impulsive 
type, inattentive type and combined type.1 However, it is 
important to note that the DSM criteria were developed based 
on childhood presentation and may not adequately represent 
symptoms in adults.9–14
The Utah criteria, developed for identification of adult 
ADHD, may be utilized as an alternative to DSM criteria. 
According to these criteria, an adult must have a childhood 
history of ADHD and current motor hyperactivity, attention 
deficits and 2 of the following: labile affect, temper outbursts, 
excessive emotional reactivity, disorganization, impulsivity 
and associated features of ADHD.15 One disadvantage 
of  these criteria is the focus on affective symptoms and 
requirement for hyperactivity, particularly given that these 
symptoms may decline more quickly over time than symp-
toms of inattention.11 Further, according to Utah criteria, 
ADHD may be diagnosed only in the absence of other 
psychiatric disorders, posing a diagnostic challenge given the 
increased incidence of comorbid psychiatric disorders.2,16
Assessment
Unfortunately, there are currently no assessments diagnostic 
of adult ADHD. Therefore, a multi-pronged approach 
including interviews, rating scales and checklists may be 
helpful in establishing a diagnosis.2,17 The first step is to be 
aware of common clinical presentations of adult ADHD. 
Adults with ADHD may present with cognitive (eg, diffi-
culty concentrating, poor memory) or affective complaints 
(eg, anxiety, irritability, depressed mood) and/or behavioral 
difficulties (eg, disorganization, failure to complete projects, 
poor school/work performance).2,3,8 Further, adults with 
ADHD experience higher rates of disruption in their interper-
sonal relationships, driving-related problems (eg, accidents, 
citations) and substance abuse.18–21 Employing a screening 
measure, such as the World Health Organization’s Adult 
ADHD Self-Report Scale Screener, may be helpful in iden-
tifying patients for further evaluation.22
Upon suspicion of an ADHD diagnosis, it is important to 
first conduct a thorough interview. Patients should be queried 
about past and present ADHD symptoms, with information 
gathered from family members and previous school records 
if possible to establish a childhood diagnosis.3,23 Functional 
impairment can be assessed by querying patients about their 
performance in a variety of situations during the prior week, 
the level of effort required to function and coping strate-
gies utilized.23–25 Assessing family history of ADHD may 
also be helpful given that ADHD has approximately 70% 
heritability.2,26 Diagnostic interviews are available to assist 
with the interview process, including the Brown ADD Scale, 
Connor’s Adult ADHD Diagnostic Interview for DSM-IV and 
the Diagnostic Interview Schedule.24 Rating scales, many of 
which require no special training and take less than 5 minutes 
to administer (eg, Brown ADD Scale for Adults, Connor’s 
Adult ADHD Rating Scale, Adult ADHD Self Report 
Scale, ADHD Rating Scale-IV), are available for administra-
tion to patients and their family members and can serve as 
useful adjuncts in the diagnostic process.22,27 Providers should 
take care to determine that symptoms are not due to other psy-
chiatric diagnoses, such as mood disorders, anxiety disorders 
and personality disorders, many of which share symptoms 
with ADHD.2,3,17,25 Routine laboratory and radiological tests Neuropsychiatric Disease and Treatment 2009:5 423
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are useful for differentiating ADHD from common medical 
conditions that can mimic symptoms of ADHD, including 
thyroid disorder, seizure disorders, drug interactions, hepatic 
diseases, lead toxicity, post-head injury, sleep disorders and 
hearing deficits.2,17 A complete blood count, metabolic profile 
and thyroid function studies can identify anemia, thyroid 
disorders or liver disorders. Routine radiological evaluation 
including computed tomography is not required for the initial 
diagnosis of ADHD and should be reserved for patients with 
a recent history of head trauma.2,17
Treatment
Similar to the diagnostic challenges mentioned above, most 
recommendations for the management of adult ADHD are 
derived from clinical experiences in childhood ADHD 
treatment. Currently, there is no practice guideline available 
in the United States for adult ADHD management. However, 
the British Association for Psychopharmacology (BAP) 
published a guideline in 2007 for ADHD management in 
adults and adolescents in transition to adult services.28
Adult ADHD results in significant functional and 
psychosocial impairment; treatment therefore consists of 
pharmacological, behavioral or combination interventions. 
As mentioned previously, comorbid psychiatric disorders 
and substance use disorders are not uncommon, posing 
unique challenges to the physician utilizing pharmacological 
management.3 Physicians’ concerns about prescribing 
medications with the potential for abuse further complicate 
and may delay initiation of appropriate treatment.29 In addi-
tion to physician bias, insurance reimbursement sources 
other than private or self-pay significantly reduce the 
likelihood of ADHD treatment, including ADHD-specific 
pharmacotherapy.6
Nonpharmacological treatment
Several behavioral strategies for assisting adults with 
managing their ADHD symptoms have been suggested, 
including organizational and time management strategies.17,30 
Though the research is still in its relative infancy, cognitive 
behavioral strategies are the most commonly investigated 
of the nonpharmacologic strategies. Cognitive-behavioral 
therapy includes identification and modification of patients’ 
maladaptive thought patterns and behaviors and has shown 
statistically significant improvements in ADHD symptoms, 
functional impairment, depression, anxiety, hopelessness, 
health status and self-esteem.30,31 Skills typically taught 
during cognitive-behavioral therapy include education about 
symptoms and medications, emotional regulation, self-esteem 
building, problem-solving skills, mindfulness and strategies 
for improving motivation, concentration, listening, 
impulsivity, organization and time management.3,30,31 It is 
important to note that cognitive behavioral therapy alone 
may be insufficient, and thus combining it with pharmaco-
logical interventions is recommended.31,32 Family therapy 
and support groups may also prove a useful adjunct in adult 
ADHD management.2,17
Pharmacologic treatment
Stimulants and atomoxetine are the mainstay of pharma-
cological adult ADHD treatment and have been shown to 
improve symptoms of ADHD and comorbid psychiatric 
disorders. They have also been shown to improve associ-
ated symptoms of adult ADHD, including self-esteem, 
social and family functioning, driving skills and substance 
use risk.32–35
The most commonly used stimulants in the treatment 
of adult ADHD include methylphenidate hydrochloride 
preparations (MPH), dextroamphetamines (DEX) and mixed 
amphetamine salts levo amphetamine and dextroampheat-
mine (AMP). Pemoline, a weak stimulant medication, has 
been withdrawn from the market because of  hepatotoxicity.36 
Stimulants have shown a response rate of 25% to 78% 
depending on the diagnostic criteria, dose of medication 
administered and the presence of comorbid psychiatric 
disorders. Response rates of greater than 75% have been 
demonstrated with higher doses of both methylphenidate 
and mixed amphetamine salts.37–40 Lisdexamphetamine 
(Vyvanse®; Shire Pharmaceuticals), the once daily prodrug 
stimulant, was approved by the United States Food and 
Drug Administration (FDA) for treatment of adult ADHD 
in 2007. In a study of 420 adults with moderate to severe 
ADHD by DSM-IV criteria, lisdexamphetamine was superior 
to placebo in all 3 doses, and patients tolerated it well with 
minimal side effects.41
Despite their benefit, it is important to note that one 
barrier to appropriate treatment with stimulant medica-
tions is physician discomfort with prescribing controlled 
substances with the potential for abuse. In one study, 38% 
of physicians surveyed preferred prescribing a nonstimulant 
medication, and 58% preferred prescribing a noncontrolled 
medication with no evidence of abuse potential in patients 
with ADHD.29
Atomoxetine, a selective noradrenergic reuptake inhibi-
tor, is the only nonstimulant medication approved by the 
FDA for ADHD treatment and has the benefit of not being a 
controlled substance. It has demonstrated efficacy in reducing Neuropsychiatric Disease and Treatment 2009:5 424
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inattentiveness, hyperactivity and impulsivity with minimal 
side effects in children and adolescents with ADHD. Among 
adults with DSM-IV criteria for ADHD, administration of 
atomoxetine in 2 randomized controlled trials of 10-week 
duration (study I, n = 280; study II, n = 256) resulted in 
significant improvements in both inattentive and hyperactive/
impulsive symptoms on the Connor’s Adult ADHD Rating 
Scales. The discontinuation rate was less than 10% in both 
the studies.42 The most common side effects were dry mouth, 
decreased appetite, insomnia, erectile dysfunction and nau-
sea with no significant cardiovascular side effects. A recent 
4-year open label study of 384 adult patients demonstrated 
statistically significant improvement in ADHD symptom 
scores with minimal side effects, demonstrating the long-term 
efficacy and safety of atomoxetine.43 Despite being recom-
mended as a first-line treatment for pediatric patients with 
ADHD because of its comparable efficacy with stimulant 
medications and low abuse potential, among adult patients 
its use has primarily been limited to patients with comorbid 
substance use, psychiatric and tic disorders.32,44
Antidepressants have demonstrated less comparable 
efficacy than stimulants in the treatment of adult ADHD. 
The response is dose-related and delayed in comparison to 
stimulant preparations.45–47 Bupropion has been the most 
extensively studied of the antidepressants. In a meta-analysis 
of 5 clinical trials comparing the efficacy of bupropion to 
placebo, bupropion was 2.4 times more likely to result in 
improved clinical outcomes.47 The alpha-agonist clonidine 
has also been used in the treatment of ADHD, primarily as 
an adjunct to stimulants in cases of comorbid aggression, 
insomnia or tics.32,48
Modafinil, a novel cognitive enhancer approved for the 
treatment of narcolepsy, has been found to improve neuropsy-
chological task performance in children and adults with ADHD 
with minimal side effects and low abuse potential. An analysis 
of 4 randomized control trials showed significant improvement 
in primary outcomes and cognitive function in ADHD patients. 
Insomnia and headache were the more common side effects, 
seen in 20% of the patients. There are no data on modafinil’s 
long-term efficacy, and hence it may be considered in patients 
with ADHD who do not respond to standard treatment.17,49
Nonstimulants can also be combined with stimulants for 
patients with inadequate response and for treatment of comor-
bid psychiatric disorders.28,32,44 Patients who fail to respond to 
appropriate doses of stimulants may have comorbid psychiat-
ric or developmental disorders; hence a careful re-evaluation 
of the patient’s diagnosis is warranted. A trial of behavioral 
therapy may be initiated prior to adding nonstimulants 
in such situations. Clonidine may alleviate symptoms of 
impulsivity or hyperactivity and sleep disturbance or tics 
from use of stimulants. Bupropion may be combined with 
stimulants for treatment of comorbid mood disorders, bipolar 
or substance use disorders.28,32,44
Methylphenidate in the management 
of adult ADHD
Psychostimulants, especially amphetamines, were the most 
effective treatment for hyperactivity syndromes in children 
from the 1930s until methylphenidate (Ritalin®) received 
FDA approval in 1968.45 Since its introduction, methylphe-
nidate has become the most prescribed medication for ADHD 
treatment in children and adults.33
Mechanism of action
Methylphenidate hydrochloride (MPH) is a piperidine 
derivative, structurally related to amphetamines. The exact 
mechanism of action of stimulants in ADHD is not com-
pletely understood, but they are presumed to act through the 
dopaminergic and adrenergic pathways of the frontostriatal 
areas in the brain.50,51 Unlike amphetamines which can cause 
a direct release of dopamine and norepinephrine into the 
presynaptic cleft, MPH is a mild central nervous system 
stimulant which acts by blocking the reuptake of dopamine 
and norepinephrine into the presynaptic cleft by blocking 
the dopamine transporter protein (DAT). MPH has also been 
shown to reduce the availability of striatal dopamine trans-
porter proteins in adults with ADHD. In 10 patients treated 
with MPH, single photon emission computed tomography 
(SPECT) imaging demonstrated that MPH lowered striatal 
DAT availability in adults with ADHD.52
MPH oral preparations are readily absorbed after oral 
administration with a peak plasma concentration in 2 hours. 
It crosses the blood–brain barrier, and 80% of the dose is excreted 
through urine as ritalinic acid, the main urinary metabolite.17
Preparations and dosage
MPH is available in short-, intermediate- and long-acting 
preparations and through a transdermal delivery system.
Short-acting preparations of MPH:
i.    Dexmethylphenidate or Focalin® (Novartis) (2.5, 5, 10 mg 
capsules)
ii.    Methylin® (5, 10, 20 mg tablets)
iii.   Ritalin® (5, 10, 20 mg).
Intermediate-acting preparations:
i.    Metadate® ER (10, 20 mg capsules)
ii.    Methylin® ER (10, 20 mg capsules)Neuropsychiatric Disease and Treatment 2009:5 425
Methylphenidate for ADHD management Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
iii.   Ritalin® SR (20 mg)
iv.   Metadate® CD (10, 20, 30, 40, 50, 60 mg)
v.    Ritalin® LA (10, 20, 30, 40 mg).
Long-acting preparations:
i.    Concerta® (Ortho-McNeil-Janssen) [extended-release 
oral osmotic release system (OROS) tablets] (18, 27, 36, 
54 mg capsules)
ii.    Focalin® XR (5, 10, 15, 20 mg capsules)
iii.   Daytrana® (Shire Pharmaceuticals), the transdermal drug 
delivery system (10, 15, 20, 30 mg patches).
Dexmethylphenidate (Focalin®) is a more potent d-threo 
enantiomer of racemic methylphenidate approved for ADHD 
treatment with a high affinity for dopamine transporter (DAT) 
and requires only half the total dose of immediate acting 
MPH preparations. Focalin® XR is the extended-release 
formulation with a bimodal release pattern with bead delivery 
system. Each capsule of Focalin® XR contains half the dose 
as immediate-release MPH beads and the other half as 
enteric coated delayed-release beads. OROS methylphenidate 
(Concerta®) was approved by FDA in 2008 for use in adults 
and uses an oral osmotic release system for its longer duration 
of action. Each capsule contains 2 drug compartments and a 
water absorption compartment. 22% of the drug is coated on 
the outside of the capsule and results in immediate relief of 
symptoms; the remaining 78% of the medication is released 
more slowly.17 Due to this unique drug delivery system it 
cannot be crushed, injected or inhaled, further reducing the 
abuse potential. Daytrana is the transdermal delivery system 
of MPH and is well tolerated. Methylin® and Ritalin® SR are 
available in generic format; Metadate® CD and Ritalin® LA 
capsules can be opened and sprinkled on soft food. All MPH 
preparations are schedule II controlled substances due to the 
potential for abuse.32
The initial starting dose is 10 mg/day for short-acting 
preparations, and the dose is titrated by 5 to 10 mg weekly to a 
maximum dose based on response and side effects (Table 1). 
The first dose is typically given in the morning with the 
additional dose in the afternoon or early evening for optimal 
symptom control. Late evening doses may exacerbate symp-
toms of insomnia and hence should be avoided. Long-acting 
preparations maybe ideal for adolescents and adults due to 
increased compliance and lesser abuse potential. Short-acting 
preparations can be combined with long-acting preparation 
for optimal symptom control during the day time.17
Efficacy of methylphenidate in adult ADHD
MPH has been shown to reduce symptoms of hyperactivity, 
impulsivity and inattentiveness and to improve on-task 
behavior, academic performance and social functioning in 
children and adolescents.32,53 Although earlier studies on 
the efficacy of MPH in the management of adult ADHD 
showed equivocal results due to low doses of medication, the 
presence of comorbid disorders and the varying diagnostic 
criteria used, recent results have been promising (Table 2).40,54 
In 1995, Spencer and colleagues conducted a randomized, 
7-week, placebo-controlled, crossover study of MPH in 
23 adult patients meeting DSM-III-R ADHD criteria. A daily 
dose of 1.0 mg/kg per day of MPH resulted in a marked 
therapeutic response as compared to placebo (78% vs 4%, 
P  0.0001) in 18 of the 23 subjects, independent of 
gender, comorbid anxiety or depression or family history of 
psychiatric disorders.40 Similar results (76% MPH vs 19% 
placebo) were reported by these authors in a later study 
of 146 adult patients with ADHD with a daily dosing of 
1.1 mg/kg/day of MPH.38 A 2004 meta-analysis of 6 studies 
(140 MPH treated adults and 113 placebo treated adults) 
showed a mean effect size of 0.9 (z = 4.3, P  0.001), which 
was similar to the effects observed with earlier studies in 
children and adolescents. Larger effect sizes (1.3, P  0.02) 
were associated with physician ratings of outcomes and larger 
doses of MPH (0.9 mg/kg/day or higher).53
Long-acting preparations have a similar efficacy rate 
with greater convenience and compliance due to single daily 
dosing.32,55–59 In one study, once daily dosing of equipotent 
extended-release OROS MPH tablets (Concerta®) had 
similar efficacy to 3 times per day dosing of immediate-
release MPH.59 In a double-blind trial of 401 adults with 
ADHD, those treated with OROS methylphenidate (18 mg, 
36 mg, or 72 mg/day), demonstrated significant improve-
ment in total symptom score as measured by Connor’s 
Adult ADHD Rating Scale (mean change = –10.6 for 18 mg, 
P = 0.01; –11.5 for 36 mg, P = 0.01; –13.7 for 72 mg, 
P  0.001; –7.6 for placebo).55 Improvement in executive 
function and oppositional/defiant symptoms has also been 
demonstrated in adults treated with OROS MPH.57,59 Most 
of the earlier studies were of short duration, thus data on 
the long-term efficacy and safety of these drugs are limited. 
However, a recent study of extended-release methylphenidate 
(methylphenidate ER) in 359 subjects for 24 weeks showed 
clinically and statistically significant sustained improvements 
in ADHD symptoms.61
Some differences in efficacy have been suggested 
depending on time of ADHD onset and ADHD subtype. 
However, in a recent study, when MPH was administered to 
children and adults meeting DSM-IV ADHD criteria, those 
meeting the childhood onset criterion had no better response Neuropsychiatric Disease and Treatment 2009:5 426
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to methylphenidate at doses of 0.5 mg/kg/day than subjects 
with late-onset ADHD (eg, not meeting the childhood onset 
criterion).62 A comparative analysis of the efficacy of MPH on 
the subtypes of ADHD in children (ADHD inattentive type vs 
ADHD combined type) indicated that MPH’s predominant 
effect was on hyperactivity and aggression in children with 
ADHD combined type. Effect on inattention and task perfor-
mance was equal among the two groups in children.63
As previously mentioned, adult ADHD patients have high 
rates of comorbid substance use disorders and, as a result, 
physicians are sometimes hesitant to initiate stimulant treat-
ment in this population. However, research indicates that 
this hesitation may not be well-founded. In a meta-analysis 
of 6 studies of children, adolescents and adults treated with 
stimulants for a minimum of 4 years (2 with follow-up in 
adolescence and 4 in young adulthood) and with informa-
tion on childhood treatment with stimulants, a substantial 
reduction in subsequent alcohol and other substance use 
disorders was found.35 Similarly, a recent 10-year prospec-
tive follow-up study of 140 children with ADHD treated 
with stimulants found no significant increase or decrease in 
alcohol, drug or nicotine use disorders.64 In patients diag-
nosed with comorbid substance use disorders, the results are 
also promising. In one study, long-acting MPH was shown 
Table 2 Efficacy of methylphenidate (MPH) in the treatment of ADHD38,53,55–58,60,61
Study N Method Duration Conclusion
Faraone53 253 Meta-analysis of 6 randomized 
placebo controlled trials
Mean effect size for MPH was 0.9  
(P  0.001) and larger effect size of 1.3 
was noticed with higher doses of MPH 
(0.9 mg/kg/day)
Spencer38 146 randomized, placebo-controlled, 
parallel study
6 weeks Therapeutic response (76% vs 19%)
Medori55 401 randomized, double blind, 
placebo controlled study of 
18, 36 and 72 mg of OrOS MPH
5 weeks Change in total score on Connor’s Adult 
ADHD rating Scale: mean change –10.6 
(P = 0.01) for 18 mg, -11.5 (P = 0.01) 
for 36 mg, and -13.7 (P  0.001) for 
72 mg vs -7.6 for placebo
rosler61 359 randomized, placebo controlled, 
parallel study of methylpheni-
date er
24 weeks response of more than 30% reduction 
of the wrAADDS score, 61% compared 
to 42% in the placebo group. 55% 
of subjects on MPH and 37% placebo 
showed improvement in CGiS
Biederman58 141 randomized placebo controlled, 
parallel study of OrOS MPH
6 week 66% of subjects (n = 44) on OrOS 
MPH and 39% of subjects (n = 23) 
on placebo showed improvement in 
CGiS and 30% reduction in Adult 
ADHD investigator System report 
Scale Score
Jain U56 50 Double blind, placebo controlled, 
cross over study using once daily 
novel biphasic multilayer release 
(MLr) methylphenidate
6 weeks improvement in CGiS (Global 
improvement: 2.6 vs 3.7; P = 0.0015), 
CAArS-S (12.2 vs 5.4; P = 0.0083), and 
CAArS-O (10.9 vs 6.6; P = 0.1404)
reimherr57 47 Double blind, placebo controlled, 
crossover trial of OrOS MPH
40% (N = 19) had ADHD with both 
significant emotional and oppositional 
symptoms. OrOS methylphenidate 
superior to placebo for all clinical 
measures: total wrAADDS score 
decrease of 42% vs 13%, P  0.001 and 
total ADHD-rS score decrease of 41% 
vs 14%, P = 0.003
Fallu60 30 Pilot, uncontrolled, open label 38 days Statistically significant improvements 
observed in executive function
Abbreviations:   ADHD-rS, Adult   ADHD-rating Scale; CAArS-S, Conners’ Adult ADHD rating Scales Self-rated; CAArS-O, Conners’ Adult ADHD rating Scales Observer 
Rated; CGI-I, Clinical Global Impressions-Improvement scale;   WRAADDS, Wender-Reimherr Adult Attention Deficit Disorder Scale.Neuropsychiatric Disease and Treatment 2009:5 428
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to be effective in controlling the symptoms of ADHD in 
patients with cocaine dependence in complete remission 
without any relapse of abuse.33 Interestingly, a 14-week 
trial comparing the efficacy of sustained-release MPH to 
placebo in the treatment of cocaine-dependent adults with 
ADHD failed to demonstrate a significant reduction in ADHD 
symptoms, but did result in a reduction in cocaine use among 
MPH-treated patients.65 However, MPH is still considered a 
second line agent for treatment of patients with adult ADHD 
and comorbid substance abuse disorder who do not respond 
to antidepressants or atomoxetine. Long-acting preparations 
with less abuse potential and close monitoring of patients is 
required if initiated on MPH.2,17,33
Comparison of methylphenidate with other 
pharmacological agents for ADHD
Data comparing the different pharmacological agents 
available for the treatment of adult ADHD are very 
limited. Most of the clinical evidence is derived from 
studies on children and adolescents. When studies among 
adults do exist, the majority are placebo-controlled trials 
and not direct comparisons of the different drugs. In a 
meta-analysis seeking to provide an indirect comparison 
of short-acting immediate-release MPH with longer-
acting stimulants, bupropion and atomoxetine, 22 placebo 
controlled trials (n = 2203) were evaluated. The relative 
risk of clinical response was 4.32 for short-acting stimu-
lants (95% CI 3.03, 6.16), 1.87 for long-acting bupropion 
(95% CI 1.36, 2.58) and 1.35 for longer-acting stimulants 
(95% CI 0.997, 1.84). The authors concluded immediate-
release MPH was more effective for the treatment of ADHD 
and comorbid substance use disorders with no significant 
adverse effects.66
Amphetamines
There are minimal data comparing the efficacy of amphet-
amines with MPH preparations in adults and children, but 
available data suggest no significant difference in efficacy, 
side effect profiles or response rates between MPH prepa-
ration and amphetamine salts.38,40,54 In a study comparing 
the efficacy of OROS MPH (72 mg), extended-release 
amphetamine salts (30 mg) and placebo in improving 
simulated driving performance among 35 adolescent drivers 
with ADHD, OROS MPH resulted in a significant improve-
ment in driving performance among adolescents with 
ADHD. Mixed amphetamine salts did not exhibit statistical 
significance over placebo in the driving performance of 
adolescents.35
Atomoxetine
There are no data directly comparing atomoxetine and MPH 
in the treatment of adult ADHD. Earlier studies in children 
and adults demonstrated response rates similar to MPH in 
ADHD symptom reduction with minimal side effects.31,42 
Despite comparable efficacy, there is some indication of 
bias in atomoxetine prescription practices. A 2006 utilization 
study compared prescribing practices of atomoxetine versus 
long-acting stimulants for adult ADHD three years after the 
introduction of atomoxetine for the treatment of adult ADHD. 
Results indicated that younger patients and females were less 
likely to receive atomoxetine, and patients with past-year 
claims for alcohol and drug dependence, psychosis, bipolar 
disorder and anxiety disorders were more likely to receive 
atomoxetine.44
Bupropion
Sustained-release bupropion has been used off-label in 
the treatment of adult ADHD, particularly when patients 
present with comorbid depression or substance abuse 
disorders. However, there are very limited data comparing 
the efficacy of bupropion to MPH in adult ADHD treatment. 
In a 7-week randomized controlled trial, adult ADHD 
symptom reduction as measured by the Clinical Global 
Impression scale was 50% for methylphenidate, 64% 
for sustained-release bupropion and 27% for placebo.67 
A 12-week trial comparing the efficacy of sustained-release 
MPH or sustained-release bupropion to placebo in treating 
ADHD symptoms in methadone-maintained subjects with 
cocaine dependence or abuse did not show any significant 
difference between treatments because of a high placebo 
response. Further, there was no misuse of medication or 
worsening of cocaine use in subjects treated with MPH.68
Clonidine
Clonidine is commonly used in the treatment of ADHD, 
particularly when patients present with comorbid aggression, 
insomnia or tic disorder. However, data on its use in adult 
ADHD are lacking. In a clinical trial of 122 children aged 
7 to 12, subjects were randomly assigned to clonidine, MPH, 
combined clonidine/MPH or placebo. Results indicated no 
significant benefit of clonidine over MPH as measured by the 
Connor’s Teachers Abbreviated Symptom Questionnaire.69
Side effects
Similar  to  other  stimulants,  MPH  can  cause  mild 
disturbances in mood, appetite and sleep which can be 
minimized by using the lowest effective dose and using Neuropsychiatric Disease and Treatment 2009:5 429
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long-acting preparations.2,17,32,33 The most common side 
effects of long-acting preparations include headache, 
decreased appetite, insomnia, nervousness and nausea.32,55,56 
Patients appear to be fairly tolerant of side effects, one 
study showing only 4.3% of patients treated with OROS 
MPH discontinuing treatment due to an adverse event.55 
MPH preparations should be used with caution in patients 
with prior history of seizure disorders as it can initiate 
seizures in higher doses.33 MPH and other stimulants are 
contraindicated in patients with glaucoma, hyperthyroidism, 
hypertension, acute psychosis and those using monoamine 
oxidase inhibitors.33
Diversion of stimulants has been a significant concern 
among physicians in initiating treatment for adult ADHD. 
These medications, particularly the short-acting preparations, 
are abused orally, through nasal insufflations after grinding 
or by injecting the dissolved drug. Approximately 7% to 11% 
of adolescents and young adults have reported diverting their 
stimulant medications. Further, approximately 11% of stu-
dents without ADHD reported using MPH or amphetamine 
for recreational purposes.70
Drug holidays, or the discontinuation of treatment during 
weekends and holidays in an effort to minimize adverse 
effects, should be discouraged due to lack of evidence 
supporting their benefit.2,8,17,32,33
Monitoring parameters
Because of the effects of MPH and other stimulants on 
weight, blood pressure and heart rate, patients’ vital signs 
should be closely monitored prior to therapy initiation and 
at periodic intervals thereafter (AHA recommendation 
Class I recommendation, level of evidence C).32,37,58,71–73 
Although adult data are not available, the estimated rate of 
sudden death in children treated with MPH between January 
1992 and December 2004 was calculated to be 0.2/100,000 
patient-years, well below the rate of sudden death in the 
general pediatric population.32 Despite this, it is important 
to exercise caution when initiating treatment. In April 2008, 
the American Heart Association recommended evaluation 
for cardiac disease in children prior to initiating therapy 
with MPH and other stimulants and atomoxetine due to 
FDA warnings of cardiac deaths in children. Most of these 
mortalities occurred in patients with underlying structural 
heart disease (eg, hypertrophic cardiomyopathy). Cases of 
sudden cardiac death have been reported when prescribing 
MPH in combination with clonidine; however, such events 
are rare when MPH is used as a single agent. Patients 
should be queried about a personal history of heart disease, 
symptoms of palpitation, dizziness or syncope and a family 
history of sudden cardiac death prior to age 40, long QT 
syndrome, arrhythmias and hypertrophic cardiomyopathy. 
A detailed medication and substance abuse history should 
be elicited prior to the initiation of treatment. A baseline 
electrocardiogram, though not mandatory, is also recom-
mended prior to initiation of stimulant treatment (Class IIa 
recommendation, level of evidence C).73
Due to the increased incidence of psychotic and manic 
symptoms among patients receiving stimulant treatment, the 
FDA warns that patients should also be monitored closely 
for psychosis and suicidal ideation while on stimulant 
medications.74 It should be noted that patients treated with 
atomoxetine should also be closely monitored for these 
symptoms, as they are more commonly reported with 
atomoxetine than MPH. Patients should also be closely 
monitored for compliance with their medication regimen 
and for medication and other substance abuse, including 
random drug screens.2,32
effect of methylphenidate on pregnancy 
and lactation
To date, there are limited human studies examining prenatal 
and breastfeeding risk. Earlier drug monitoring studies did 
not observe increased incidence of birth defects due to MPH 
exposure.75 The National Toxicology Program Center for 
the Evaluation of Risks to Human Reproduction reported in 
2005 that there are insufficient data for pregnancy loss and 
reproductive effects with MPH use in pregnancy.76 However, 
because of limited human data and animal data suggesting 
moderate risk during pregnancy, all stimulants (includ-
ing MPH) carry category C risk in pregnancy.75,76 Despite 
potential for risk, there is no recommendation for termina-
tion of pregnancy for maternal exposure to MPH. However, 
patients should be closely monitored and counseled about 
the possibility of emergence of symptoms or unfavorable 
physiological side effects (such as changes in heart rate, 
blood pressure) owing to sudden withdrawal of stimulant 
drugs during pregnancy.79
Data on MPH safety during lactation is limited, but it is 
presumed to be passed to the nursing infant due to its low 
molecular weight. The American Academy of Pediatrics 
recommends against breastfeeding while on MPH and other 
stimulant medications.75
Cost
Earlier cost and efficacy studies of drug treatments for 
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differences among treatments; however, immediate-release 
MPH and extended-release MPH preparations had lower 
total expected costs.78,79 In a 6-month follow up of 4569 
patients receiving 3 alternative drug therapies for ADHD 
(OROS MPH, extended-release mixed amphetamine salts, 
atomoxetine), adults treated with OROS MPH had slightly 
lower medical and total medical and drug costs than those 
treated with MAS-XR or atomoxetine after adjusting for 
patient characteristics including substance abuse, depression, 
and comorbid disorders. The comparison of risk-adjusted 
total direct costs, including drug cost, was on average 
US$156 less (8.0%, US$1,782 vs US$1,938) for OROS-
MPH compared with extended-release mixed amphetamine 
salts (P = 0.017) and $226 less (11.3%, $1,782 vs. $2,008) 
compared with atomoxetine (P  0.001).80
Conclusions
Adult ADHD causes academic, occupational and social 
dysfunction with significant economic burden to society. 
Currently, there are no national guidelines to aid physi-
cians in the diagnosis and management of adult ADHD, 
and most of the treatment principles are based on evidence 
from childhood ADHD treatment. In spite of the advent of 
longer-acting and nonstimulant medications for the treatment 
of ADHD, MPH remains the most cost-effective treatment 
with clinically significant outcomes. Amid concerns for 
diversion of drugs for potential abuse, MPH (particularly 
short-acting, immediate-release MPH) has been shown to 
decrease substance use disorders in children and young 
adults. Long-acting preparations are beneficial because of 
their potential for increased compliance and lower potential 
for abuse. Compared with the childhood ADHD literature, 
there is a significant paucity of evidence on the cardiovas-
cular and psychiatric adverse effects in adults. Further, there 
is limited evidence of the comparative efficacy, including 
long-term efficacy, and safety of different pharmacological 
agents. Until more data are available, immediate-release and 
long-acting MPH and other stimulant medications remain the 
mainstay of treatment for adult ADHD.
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